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Longitudinal [ 18 F]FMPEP-d 2 PET imaging
Introduction 1
Alzheimer's disease (AD) is an age-related neurodegenerative disease characterized by progressive memory loss, 2 cognitive decline, and the accumulation of neuritic β-amyloid (Aβ) plaques and neurofibrillary tangles, associated with 3 elevated neuroinflammation and oxidative stress (Ball, 1976; Glenner, et al., 1984) . Strong evidence of alterations in the 4 endocannabinoid system (ECS) in the pathogenesis of AD has raised questions about the development of novel 5 therapeutic approaches for AD based on endocannabinoid regulation (Fagan and Campbell, 2015) . The ECS is 6 composed of a relatively broad set of receptors, endogenous ligands, and enzymes, which are involved in AD 
17
Moreover, a recent study demonstrated no differences in CB 1 R activity in 13-to 14-month-old female APP SWE /PS1 ∆E9 18 mice compared with wild-type (WT) mice (Karkkainen, et al., 2012) , whereas in 3xTg-AD mice, thalamic CB 1 R 19 activity was up-regulated at 4 months of age, but not in older animals (Manuel, et al., 2016 detecting the involvement of the CB 1 R system in alcohol dependence (Hirvonen, et al., 2013) . In AD research, the 5 applicability of this tracer has yet to be examined.
6
Despite the difficulties of developing suitable PET radioligands for imaging CB 1 Rs in vivo, the need is urgent for 7 reliable research tools for studying the role of the endocannabinoid system in neurological diseases. M A N U S C R I P T Longitudinal data were obtained by in vivo PET imaging using APP/PS1-21 mice (n = 8, male) and WT control 10 littermates (n = 8, male). The mice underwent PET scans at 6, 9, 12, and 15 months of age using a 1.4-mm spatial 11 resolution Inveon Multimodality PET/CT scanner (Siemens Medical Solutions, Knoxville, TN, USA).
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The detailed in vivo study design is presented in Figure S1 . 
27
The detailed ex vivo study design is presented in Figure S1 . within the same subject to gain radioactivity ratios for each region of interest, which are referenced as binding ratios. 8
Radiometabolite analyses 9
The metabolite analyses were performed with 3-to 4-month-old male C57BL/6Cn mice (n TOTAL = 15) at 15 
Western blot 25
The detailed western blot study protocol is presented in S2. Briefly, the CB 1 R abundance in the FC, PTC, HIPPO, and
26
THALA was quantified in 9-month-old TG (n TOTAL = 7; 3 males) and WT (n TOTAL = 6; 3 males) mice. The brain regions 
6
The fluorescent signals were analysed by Image Studio Software Lite v. 5.2 (LI-COR, Inc.) and the signal intensities 7
were normalized to the housekeeping protein in each membrane. 8
CB 1 R immunohistochemistry 9
The localization of the CB 1 Rs was visualized by staining the brain sections collected from ex vivo autoradiography. CB, and HIPPO of 9-month-old TG mice; in the B, PTC, and HIPPO of 12-month-old TG mice; and in the FC and PTC 6 of 15-month-old TG mice (n = 7) compared to age-matched WT mice (n = 6) in the intergroup analysis (Fig. 1 ).
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The mean [ 18 F]FMPEP-d 2 binding ratio changes in the PTC differed significantly between TG and WT mice from 6 to 9 8 months of age, 6 to 12 months of age, and 6 to 15 months of age (Fig. 1a) . The mean binding ratio changes in the 9 HIPPO differed, though not significantly (p = 0.0669), between TG and WT mice from 6 to 9 months of age. In the 10 other brain regions, the differences in mean binding changes did not vary throughout the longitudinal study because 11 significant intergroup differences in binding between the TG and WT mice were already present at 6 months of age. Table S3 .
19
In males, significantly lower binding ratios were observed in STR of 15-month-old TG mice (n = 10) compared to age-20 matched male WT mice (n = 6) ( Fig. 2) . No significant differences were observed in other brain regions, although 21 similar trend was seen in 9, 12, and 15-month-old male TG mice. In 9-month-old female TG mice (n = 6), significantly brain were 2.46 and 2.55 %ID/g in rimonabant-treated mice (n = 2), whereas in saline-treated mice, the amounts of 18 F-7 radioactivity were 7.57 and 7.44 %ID/g (n = 2). Therefore, the displacement with rimonabant was 67% in mouse brain ,   8 which was also demonstrated in in vivo concentration analyses of 18 F-radioactivity as a function of time (Fig. 4) .
Regional CB 1 R expression is unchanged between APP/PS1-21 and WT mice 10
Female (n = 7, 4 TG) and male (n = 6, 3 TG) mice were significantly differentiated (p < 0.0001) in terms of CB 1 R 11 expression in FC, PTC, and THALA at 9 months of age (Fig. 5, S4 ). In detail, female mice exhibited 2.7-fold (FC), 4.0-12 fold (PTC), and 2.2-fold (THALA) higher receptor expression compared to male mice. In contrast, no differences were 13 seen between TG and WT mice, neither in females nor males. In HIPPO, no significant differences were seen between 14 the genders or genotypes. 
Discussion 22
The comprehensive aim of this study was to investigate the role of CB 1 Rs in aging APP/PS1-21 mice using longitudinal 23 
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